---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-013412"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:27:37.256816+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out

## Summary
- Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.
- Steve Crouse, previously SVP of Analytical Solutions, named successor; he joined in 2022 from Thermo Fisher Scientific.
- Crouse's employment agreement includes base salary of $505,000, target cash bonus of 75% of base, and equity awards valued at ~$170,000 one-time and ~$1.2M annual target.
- McManus's termination approved without cause; he will receive severance per employment agreement.

## SEC filing metadata
- accession: 0001104659-26-013412
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000110465926013412/0001104659-26-013412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000110465926013412/tech-20260209x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-013412
- JSON: https://secwatch.observer/filing/0001104659-26-013412.json
- Plain text: https://secwatch.observer/filing/0001104659-26-013412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.